Document:

<PAGE>
                                                                    EXHIBIT 10.4

                     SCHEDULE TO INDEMNIFICATION AGREEMENT

      The following is a list of the current directors and executive officers of
Antigenics who are party to an Indemnification Agreement, the form of which was
filed as Exhibit 10.4 to our registration statement on Form S-1 (File No.
333-91747):

Garo H. Armen, Ph.D.
Pramod K. Srivastava, Ph.D.
Peter Thornton
Russell H. Herndon
Renu Gupta
Roman Chicz
Noubar Afeyan, Ph.D.
Frank V, AtLee III
Gamil G. de Chadarevian
Tom Dechaene
Margaret Eisen
Wadih Jordan
Mark Kessel
Alastair Wood<PAGE>
                                                                   EXHIBIT 10.8

                               RESEARCH AGREEMENT

This Agreement is made by and between:

Antigenics, L.L.C., a limited liability company organized and existing under the
laws of the State of Delaware, having an office at 630 Fifth Avenue, Suite #
2170, New York, NY 10111, hereinafter referred to as Sponsor.

                                       and

The University of Connecticut Health Center, an agency of the State of
Connecticut, having a business address at 263 Farmington Avenue, Farmington,
Connecticut, 06030, hereinafter referred to as UCHC.

                                       and

Pramod Srivastava, Ph.D., Professor of Immunology, and Director, Center for
Immunotherapy of Cancer and Infectious Diseases, University of Connecticut
Health Center, having a business address at MC-1601, University of Connecticut
Health Center, 263 Farmington Avenue, Farmington, Connecticut, 06030,
hereinafter referred to as Principal Investigator.

         The purpose of this Agreement is to promote the increase of useful
knowledge relating to a project entitled, "Use of heat shock proteins for the
development of therapeutic and prophylactic vaccines for cancer and infectious
diseases."

                                  IT IS AGREED:

1.0      The UCHC agrees to undertake certain research (hereinafter referred to
         as the Project) specifically described in the attached proposal
         (Appendix A) which by reference is incorporated into this Agreement,
         and such other work as may be mutually agreed upon in a duly executed
         amendment to this Agreement.

2.0      The Project and all work assignments shall be carried out under the
         direction of the Principal Investigator, while employed by UCHC, and by
         other research staff employed by UCHC (e.g. technician, graduate
         student, postdoctoral follow, staff assistant, hereinafter collectively
         referred to as Personnel), as assigned by Principal Investigator.

3.0      The Project covered by this Agreement shall commence on February 12,
         1998 and shall extend for a period of 58.5 months, expiring on December
         31, 2002.

4.0      UCHC agrees to furnish such available facilities as it shall determine
         necessary for the work to be done on this Project. During the term of
         this Agreement, UCHC and the Principal Investigator will permit, upon
         reasonable notice and at reasonable times, representatives of Sponsor
         to observe research facilities utilized for and research performed by
         Principal Investigator pursuant to this Agreement.

<PAGE>

5.0      Sponsor agrees to pay UCHC the sum of $5,000,000 for this Project in
         accordance with the agreed budget (Appendix B), plus any agreed to
         excess costs as evidenced by a writing signed by both parties; payments
         to be made as follows:

         $250,000     Payable upon execution of Agreement
         $250,000     Payable by no later than May 15, 1998
         $250,000     Payable by no later than August 15, 1998
         $250,000     Payable by no later than November 15, 1998

         Payments for all subsequent years shall be due by no later than
         February 15, May 15, August 15, and November 15 of each year.

         Sponsor further agrees to pay preaward costs incurred by Dr. Srivastava
         upon submission of an invoice in an amount not to exceed $475,000.
         Payment of said preaward costs shall be made within ten day of
         Sponsor's receipt of the invoice.

         5.1      Payments are to be made to:

                  University of Connecticut Health Center
                  Grant and Contract Administration
                  ASB3, MC 5335
                  263 Farmington Ave.
                  Farmington, CT 06030
                  Attn.: Ken Landorf, Manager
                  IRS No.: 52-1725543

6.0      The Principal Investigator shall furnish Sponsor with written reports
         on the progress of the work on dates as mutually agreed upon and a
         final report on the entire Project within ninety (90) days after
         termination of this Agreement.

7.0      The data and information accruing from the Project may be published in
         writing or orally presented by the Principal Investigator, but Sponsor
         shall be provided with a copy of any proposed written manuscript at
         least thirty (30) day prior to submission or the text of any oral
         disclosure at least fourteen (14) days prior to its presentation and
         shall have thirty (30) days in the case of written manuscripts and
         fourteen (14) days in the case of oral presentations for review of
         patentable items or items deemed confidential and proprietary as
         defined in Article 8.0.

         7.1      If Sponsor believes that any planned publication contains a
                  patentable development, publication, or presentation shall be
                  delayed for a reasonable time to permit the filing of a patent
                  application(s). If the patent application is prepared under
                  direction of UCHC, counsel approved by the Sponsor from the
                  list of firms

                                       2
<PAGE>

                  having Professional Employment Agreements with the Attorney
                  General of the State of Connecticut for the purposes of patent
                  preparation, prosecution and maintenance of University of
                  Connecticut inventions conceived or reduced to practice in the
                  conduct of the Project shall be used. Sponsor shall have the
                  right to elect to use its own counsel who will then conduct
                  such patent preparation, prosecution, and maintenance. If
                  Sponsor elects to use its own counsel, said counsel shall be
                  subject to UCHC approval, which approval shall not be
                  unreasonably withheld. When such election has been approved by
                  UCHC, Sponsor, and Sponsor's counsel, or their agents shall
                  provide UCHC and its agents on a timely basis with copies of
                  all correspondence and patent application submissions
                  (including but not limited to parent, continuation,
                  continuation-in-part or reissue applications) by and between
                  Sponsor and Sponsor's counsel and/or agents and the U.S.
                  Patent and Trademark Office. Notwithstanding the preceding
                  service requirement, Sponsor and Sponsor's counsel and/or
                  agents shall make diligent efforts to provide all such
                  correspondence and applications to UCHC or UCHC's agents prior
                  to their submission and shall to the extent practicable
                  consult with UCHC and its agents regarding the form of such
                  submissions. UCHC acknowledges and approves Sponsor's election
                  to use as patent counsel the firm of Pennie and Edmonds, New
                  York, NY.

         7.2      Sponsor shall reimburse UCHC for all costs associated with
                  UCHC's filing, prosecution and maintenance of patents arising
                  form this work pursuant to Sponsor's request that is carried
                  out by UCHC counsel. If Sponsor has elected to use it's own
                  counsel and UCHC has approved such election, Sponsor shall
                  directly pay all costs associated with the preparation,
                  submission and maintenance of the resulting patent carried out
                  by its counsel.

         7.3      UCHC and the Principal Investigator shall not disclose to
                  other or publish any information disclosed to the Principal
                  Investigator by Sponsor which is confidential within the
                  meaning of Article 8.0 without the prior written approval of
                  Sponsor.

8.0      UCHC and Principal Investigator agree to hold in confidence all
         information which Sponsor may wish to disclose to Principal
         Investigator in writing and marked "CONFIDENTIAL" under this Agreement
         except:

                  a.       technical information which at the time of disclosure
                           publicly known or available;

                  b.       technical information which after disclosure is
                           published or otherwise becomes publicly known or
                           available through no fault of Principal Investigator;

                  c.       technical information which was in the possession of
                           the Principal Investigator at the time of disclosure
                           and was not acquired from Sponsor under an obligation
                           of confidence.

                                       3
<PAGE>

9.0      Sponsor shall retain patent rights to all of its technologies currently
         protected by existing patents or pending patent applications, and for
         technologies developed by Sponsor outside the terms of this Agreement.

         9.1      Pursuant to the work performed under this Agreement UCHC shall
                  retain patent rights to all new technologies developed as a
                  result of intellectual contributions of UCHC's faculty or
                  staff or involving the use of UCHC facilities or resources.

         9.2      UCHC shall provide Sponsor with a copy of each written
                  invention disclosure of intellectual property conceived or
                  developed in the conduct of the Project within forty five (45)
                  days of its submittal to the UCHC, in sufficient detail so as
                  to enable one skilled in the art to understand the subject
                  matter of the invention. The UCHC shall also notify Sponsor
                  immediately of any potential statutory bar, including but not
                  limited to, the dates of any publication, presentation or
                  other disclosure of the intellectual property accruing to the
                  project.

         9.3      For new inventions, other than incremental improvements which
                  are dominated by existing patents or pending patent
                  applications for which Sponsor holds a license, UCHC agrees to
                  grant and hereby grants to Sponsor an option to secure a
                  royalty-bearing exclusive license, including the right to
                  grant sublicenses, under reasonable terms with the right to
                  make, use and sell, have made, have used, import and offer for
                  sale the claimed invention of any patent or patent application
                  which is based on any invention conceived or reduced to
                  practice in the conduct of the Project, subject to Article 9.1
                  above. The license (and all sublicenses) will include a
                  royalty rate in an amount to be negotiated in good faith by
                  both UCHC and Sponsor at the time the Sponsor decides to
                  exercise its option and shall remain in effect until the
                  expiration of the last to expire patents licensed to the
                  Sponsor. Such option shall be in effect and exercisable for
                  each invention within one hundred and eighty (180) days from
                  the date of filing a U.S. patent application on each such
                  invention. Upon exercise of such option, the terms and
                  conditions of the license will be negotiated in good faith by
                  the parties. In the absence of agreement within six (6) months
                  from the date of exercise of such option, which time shall be
                  extended upon mutual written agreement, the dispute shall be
                  submitted to a mutually acceptable third-party mediator, which
                  period of mediation shall not exceed 90 days or such longer
                  period as may be mutually acceptable to the parties.

         9.4      For inventions which are incremental improvements dominated by
                  existing patents or pending patent applications for which
                  Sponsor holds a license, UCHC agrees to grant and hereby
                  grants to Sponsor an option to secure a royalty-bearing
                  exclusive license with the right to make, use and sell, have
                  made, have used, import and offer for sale the claimed
                  invention conceived or reduced to practice in

                                       4
<PAGE>

                  the conduct of the Project. Such option shall be in effect and
                  exercisable within one hundred and eighty (180) days from the
                  date of filing a U.S. Patent Application on each such
                  invention. In the case of Licensed Products that incorporate
                  the UCHC Technology but are dominated by patent applications
                  licensed by Sponsor from one other third party, Sponsor shall
                  pay UCHC a royalty calculated at the rate of [        ]* of
                  Net Sales of Licensed Product. In the case of Licensed
                  Products that incorporate the UCHC technology but are
                  dominated by patent applications licensed by Sponsor from two
                  or more third parties, Sponsor shall pay UCHC a royalty
                  calculated at the rate of [        ]* of Net Sales of Licensed
                  Product. Upon exercise of such option, the remaining terms and
                  conditions of the license will be negotiated in good faith by
                  the parties. In the absence of agreement within six (6) months
                  from the date of exercise of such option, which time period
                  shall be extended upon mutual written agreement, the dispute
                  shall be submitted to a mutually acceptable third-party
                  mediator, which period of mediation shall not exceed 90 days.

         9.5      For the purposes of this Article 9 the terms, Licensed Product
                  and Net Sales shall be defined as follows:

         o        Affiliates are defined as any entity which controls, is
                  controlled by or is under common control with Licensee. An
                  entity shall be regarded as in control of another entity if it
                  owns or controls more than fifty percent (50%) of the voting
                  power of such entity.

         o        Licensed Product(s) means any method, procedure, process,
                  product, or component part thereof conceived or developed by
                  UCHC in the conduct of the Project whose manufacture, sale,
                  use, importation, or offer for sale is covered by the claim of
                  a pending patent application or which could be construed to
                  infringe the licensed patent in the absence of the license.

         o        Net Sales means total billings for Licensed Product(s),
                  determined in accordance with generally accepted accounting
                  principles, sold by Licensee, its Affiliates and sublicensees,
                  less: (a) discounts allowed in amounts customary in the trade;
                  (b) sales, tariff duties and/or use taxes directly imposed and
                  with reference to particular sales; (c) outbound
                  transportation prepaid or allowed; and (d) amounts allowed or
                  credited on returns. Licensed Products shall be considered
                  "sold" when billed out or invoiced. Sales of Licensed
                  Product(s) between or among Licensee, its Affiliates and
                  sublicensees shall not be subject to any royalty hereunder,
                  and in such cases royalties shall be calculated upon
                  Licensee's or its Affiliates' or sublicensees' Net Sales to an
                  independent third party. Licensee shall be responsible for
                  payment of any royalty accrued on Net Sales of Licensed
                  Products to such independent third party through Licensee's
                  Affiliates or

______________________

* This portion of the Exhibit has been omitted pursuant to a Request for
Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended.
The complete Exhibit, including the portions for which confidential treatment
has been requested, has been filed separately with the Securities Exchange
Commission.

                                       5
<PAGE>

                  sublicensees. Royalties shall accrue hereunder only once in
                  respect of the same unit of the Licensed Product.

         9.6      As to all licenses which may be granted by UCHC to Sponsor
                  under the terms of this Agreement, UCHC retains a perpetual
                  royalty-free non-exclusive right to use the licensed property,
                  product, procedure or process and to use the licensed UCHC
                  technology for basic and clinical research, and the
                  educational purposes of the UCHC, and not for any commercial
                  purpose.

10.0     UCHC and Sponsor agree that the Principal Investigator and Personnel
         are acting as employees of UCHC and not as agents or employees of
         Sponsor.

11.0     No advertising or publicity matter having or containing any reference
         to either party shall be used by the other party without advanced
         written authorization. Notwithstanding the afore-stipulated
         restrictions, Sponsor may use publications containing the name of UCHC
         and other documentation (abstracts, poster presentations, etc.) which
         are generally accessible to the public without the further review and
         consent of UCHC. All other advertising and publicity matter shall be
         submitted to the Office of the Vice Chancellor for Research for review
         prior to its use or public release. Said documentation shall be
         reviewed expeditiously, and in no event shall such review be
         unreasonably delayed. In addition, UCHC may disclose the sponsorship,
         title, duration and total budget of this project in UCHC's "Annual
         Report of Research and Scholarly Activity," and in such other reports
         as may be required by the UCHC's Administration, Board of Trustees or
         by the Board of Governors of Higher Education.

12.0     UCHC agrees that there shall be no change in the Principal Investigator
         without prior written approval of Sponsor.

13.0     It is understood that the Project may be extended for additional
         periods of time under terms mutually agreed upon in writing in a duly
         executed amendment to this Agreement.

         13.1     Renewal proposals shall be submitted by UCHC to Sponsor at
                  least ninety (90) days prior to the expiration of this
                  Agreement.

         13.2     Sponsor agrees to give UCHC notice of its intention to
                  continue the Project not less than sixty (60) days prior to
                  the expiration date specified in Article 3.0 hereof or in a
                  later amendment to this Agreement.

14.0     If UCHC is unable to fulfill the terms of this Agreement, then UCHC may
         terminate the Agreement by giving sixty (60) days notice to Sponsor. If
         Pramod Srivastava is unable to continue as Principal Investigator, or
         terminates his employment by UCHC, Sponsor shall have the right to
         terminate this Agreement by giving thirty (30) days notice to UCHC.

         14.1     Upon termination of this Agreement, unexpended funds
                  appropriate by Sponsor to UCHC shall be returned to Sponsor
                  except for outstanding, unpaid commitments to a third
                  party(ies) or to Personnel engaged in the conduct of the
                  Project which

                                       6
<PAGE>

                  cannot be canceled or otherwise terminated. Upon issuance of
                  notice, UCHC shall not enter into any material new commitments
                  or obligations related to the Project without consent of the
                  Sponsor.

         14.2     Termination of this Agreement shall not affect the rights and
                  obligations of the parties in inventions conceived or made in
                  the conduct of the Project prior to termination.

15.0     This Agreement shall be binding upon and inure to the benefit of the
         respective parties and their successors.

16.0     This Agreement shall be governed by and construed according to the laws
         of the State of Connecticut; including, but not limited to the
         following:

                  a.       Non-discrimination Section 4.1 14a of the General
                           Statutes of Connecticut, as amended. UCHC in its
                           employment practices under this grant Agreement will
                           not discriminate or permit discrimination against any
                           person or group of persons on the grounds of race,
                           color, religious creed, age, marital status, national
                           origin, sex, mental retardation, or physical
                           disability (including but not limited to blindness)
                           unless it is shown that such disability prevents
                           performance of the work involved, in any manner
                           prohibited by the laws of the United States or of the
                           State of Connecticut.

17.0     UCHC is authorized to enter into this Agreement under Section 10a-104,
         10a-110 to 10a-l10g of the General Statutes of Connecticut as amended
         to date.

18.0     Sponsor agrees to indemnify, hold harmless, and pay all legal and other
         costs or losses incurred by Principal Investigator and Personnel, as
         investigator(s) in this study, and UCHC as the host institution,
         against any claim or legal cause of action brought against Principal
         Investigator, Personnel and UCHC arising out of the use by Sponsor, or
         by any party acting on behalf of or under authorization from Sponsor,
         sale or other disposition by Sponsor, or by any party acting on behalf
         of or under authorization from Sponsor of products made as a result of
         work conducted under this Agreement.

         UCHC agrees to notify Sponsor as soon as it becomes aware of a claim or
         action and to cooperate with and to authorize Sponsor to carry out sole
         management and defense and settlement of such claim or defend against
         any actions brought or filed against its trustees, officers, agents and
         employees with respect to the subject of indemnity contained herein,
         whether such claims or actions are rightfully brought or filed.

         Neither UCHC, nor its trustees, officers, agents or employees shall
         compromise or settle any claim or suit related to the Project of this
         Agreement without the prior written approval of Sponsor.

         This Agreement will govern claims brought subsequent to the termination
         date of this Agreement. This provision shall survive the completion or
         termination of this project since it cannot be presently ascertained
         when the last claim will be filed.

                                       7
<PAGE>

19.0     Any notice required to be given hereunder shall be considered properly
         given if sent by certified letter, first class mail, postage prepaid,
         to the respective address of each party indicated at the beginning of
         this Agreement, or to such address as the addressee shall have last
         furnished in writing to the addressor in like manner.

20.0     Sections 7, 8, 9, 11, 15, 16, 18 and 19 shall survive termination or
         expiration of this Agreement.

21.0     It is understood that UCHC and the Principal Investigator and Personnel
         may be or become involved in other activities and projects which entail
         commitments to other sponsors; however, UCHC represents and warrants
         that the Principal Investigator and Personnel are not presently
         performing, and will not perform during the term of this Agreement,
         research relating to the Project (see Appendix A) that is sponsored by
         a commercial, for-profit, third party to whom UCHC is obligated to
         grant rights in any invention or discovery resulting therefrom,
         excluding Government rights pursuant to 35 U.S.C. ss.ss. 200 et seq.
         resulting from federal grant funding or a similar reservation of rights
         pursuant to grant funding from the State of Connecticut or other
         non-profit entities.

22.0     The Project will not be conducted in collaboration with a researcher
         who is not associated with UCHC, unless Sponsor has given prior written
         approval of such collaboration.

23.0     The parties hereto have caused this Agreement to be executed by duly
         authorized representatives effective as of the later date indicated
         below.

ANTIGENICS, L.L.C. - "SPONSOR"

 /s/ Garo Armen                          2/18/98
------------------------------          ------------------------------
        (Signature)                                 (Date)

Name: Garo Armen
      ------------------------

Title: CEO
       -----------------------

UNIVERSITY OF CONNECTICUT HEALTH CENTER - "UCHC"

 /s/ Leonard Paplauskas                  2/17/98
------------------------------          ------------------------------
        (Signature)                                 (Date)

Name:  Leonard P. Paplauskas

Title: Assistant Vice Chancellor for Research

                                       8
<PAGE>

/s/ Pramod Srivastava                    2/16/98
------------------------------          ------------------------------
        (Signature)                                 (Date)

Name:  Pramod Srivastava, Ph.D.

Title: Professor, Center for Immunotherapy of Cancer and Infectious Disease

                                       9
<PAGE>

                                   APPENDIX A

                                  SCOPE OF WORK

<PAGE>

                       Scope of work for ANTIGENICS grant

[

                                                                     ]*
         [
                                                            ]*

______________________

* This portion of the Exhibit has been omitted pursuant to a Request for
Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended.
The complete Exhibit, including the portions for which confidential treatment
has been requested, has been filed separately with the Securities Exchange
Commission.
<PAGE>

[
         ]*

______________________

* This portion of the Exhibit has been omitted pursuant to a Request for
Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended.
The complete Exhibit, including the portions for which confidential treatment
has been requested, has been filed separately with the Securities Exchange
Commission.

<PAGE>

[

                                                    ]*

______________________

* This portion of the Exhibit has been omitted pursuant to a Request for
Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended.
The complete Exhibit, including the portions for which confidential treatment
has been requested, has been filed separately with the Securities Exchange
Commission.

<PAGE>

                                   APPENDIX B

                                     BUDGET

                              For Each of 5 Years

                               2/12/98 - 12/31/02

SUB CODE               DESCRIPTION                     BUDGET

1000                   Salaries                        $  315,000

2000                   Purchased Services              $  125,000

3000                   Supplies & Minor Equipment      $  188,151

4000                   Sundry (Fringe Benefits)        $   65,500

9000                   Capital Equipment               $  100,000

                       Indirect Cost                   $  206,349

                       TOTAL                           $1,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]